Economic impact of new interventional therapies: are we asking the right questions?

J Am Coll Cardiol. 2004 Nov 2;44(9):1809-11. doi: 10.1016/j.jacc.2004.08.010.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Angioplasty, Balloon, Coronary / economics*
  • Anticoagulants / economics*
  • Anticoagulants / therapeutic use*
  • Coronary Disease / economics*
  • Coronary Disease / therapy*
  • Cost-Benefit Analysis
  • Embolism / economics*
  • Embolism / prevention & control*
  • Heparin / economics*
  • Heparin / therapeutic use*
  • Hirudins / analogs & derivatives*
  • Hirudins / economics*
  • Hospitalization / economics
  • Humans
  • Peptide Fragments / economics*
  • Peptide Fragments / therapeutic use*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Platelet Glycoprotein GPIIb-IIIa Complex / economics
  • Platelet Glycoprotein GPIIb-IIIa Complex / therapeutic use*
  • Postoperative Complications / economics*
  • Postoperative Complications / prevention & control*
  • Recombinant Proteins / economics*
  • Recombinant Proteins / therapeutic use*
  • Saphenous Vein / pathology*
  • Saphenous Vein / surgery*

Substances

  • Anticoagulants
  • Hirudins
  • Peptide Fragments
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Recombinant Proteins
  • Heparin
  • bivalirudin